NEW YORK (GenomeWeb News) – Theradiag today announced that Oséo has provided it €1.2 million ($1.6 million) to develop new diagnostic kits as part the French firm's participation in a project to develop RNA-targeting therapeutics and diagnostics aimed at HIV/AIDS and obesity.

Oséo, the French Agency for Innovation, is providing funding to Theradiag for work that will be done as part of its participation in CaReNA, a collaboration among drug development firm Splicos, Theradiag, and the French National Center for Research and Science.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.